The Kansas City Clinical Oncology Program (KCCOP), now in its twelfth year of operation, is a consortium of twelve member hospitals whose purpose is to develop and sustain city-wide support for cancer research and treatment programs and to promote the highest quality of cancer care thereby benefiting cancer patients and their families throughout the metropolitan area. This current program is the result of a merger between one of the nation's best performing CCOPs and one of the top CGOPs (the Midwest CGOP) which combines the efforts of over 50 dedicated community clinical investigators. The KCCOP has a positive record of accrual to clinical trials with numbers of patients and credits well in excess of the minimums required by the NCI. Over the past four years, KCCOP investigators have accrued 428 patients to therapeutic 243 patients to cancer control trials, for a total of 471.6 and 152.1 credits, respectively. The KCCOP has access to a large population base which will ensure continued high accruals to treatment and cancer control trials. The combined program has also increased KCCOP's ability to reach underserved and minority groups within the metropolitan area. The twelve member institutions and the physician investigators of the KCCOP remain committed to the advancement of NCI research. This dedication and the presence of an experienced staff will allow the KCCOP to reach the projected accrual goals on therapeutic and cancer control research trials and to continue our involvement in the scientific portion of cooperative group activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
7U10CA035176-16
Application #
2894571
Study Section
Special Emphasis Panel (SRC (16))
Program Officer
Cornelison, Terri L
Project Start
1983-09-15
Project End
2000-05-31
Budget Start
1999-06-10
Budget End
2000-05-31
Support Year
16
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Kansas City Clinical Oncology Program
Department
Type
DUNS #
148680262
City
Kansas City
State
MO
Country
United States
Zip Code
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8

Showing the most recent 10 out of 147 publications